This service precisely supports the entire new drug development process through patient response prediction, candidate substance efficacy evaluation, and mechanism of action analysis. By utilizing organoids similar to human tissues, it is expected to increase the likelihood of new drug approval and contribute to improving clinical success rates. Moving beyond its existing Contract Development and Manufacturing Organization (CDMO) services, Samsung Biologics now offers a one-stop service from target discovery to clinical trial planning. Based on its accumulated production and development expertise, Samsung provides customized data-driven analysis, enabling rapid verification of new drug candidates' potential. The company is also expanding its efforts to attract global pharmaceutical partners by emphasizing practical benefits such as biomarker discovery, preclinical efficiency improvement, and accelerated approval timelines. This service is based on the convergence of AI and organoid technologies and is expected to serve as a core infrastructure for the era of personalized medicine. Samsung Biologics plans to further strengthen its competitiveness in the global bio market through this initiative. For companies like HADD Science, which research organoid-based technologies, this could present opportunities for collaboration and benchmarking.